Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301
详细信息 查看全文
- 作者：Shinya Sakataa ; b ; Sho Saekia ; Isamu Okamotob ; okamotoi@kokyu.med.kyushu-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Kohei Otsubob ; Kazutoshi Komiyac ; Ryotaro Morinagad ; Yasuto Yoneshimab ; Yuichiro Kogab ; Aimi Enokizub ; Hiroto Kishie ; Susumu Hirosakoa ; Emi Yamaguchia ; Naoko Araganec ; Shinji Fujiif ; Taishi Haradab ; Eiji Iwamab ; g ; Hiroshi Sembaf ; Yoichi Nakanishib ; Hirotsugu Kohrogia
- 关键词：Non&ndash ; small cell lung cancer ; Nab-paclitaxel ; Objective response rate ; Overall survival ; Phase II trial
- 刊名：Lung Cancer
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：99
- 期：Complete
- 页码：41-45
- 全文大小：639 K
文摘
- •
This is a phase II study of nab-paclitaxel in patients with previously treated NSCLC.
- •
The ORR was 31.7%, which met the primary objective of the study.
- •
The median PFS was 4.9 months and the median OS was 13.0 months.
- •
Hematologic toxicities of grade 3 or 4 was neutropenia (19%) and leukopenia (17%).
- •
Nab-paclitaxel showed acceptable toxicity and favorable ORR.